Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers

Radiomic signatures to predict response to targeted therapy and immune checkpoint blockade in melanoma patients (pts) on neoadjuvant therapy.

(2020) Rivka R. Colen et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 2 study of pembrolizumab in patients with advanced rare cancers

(2020) Aung Naing et al.   Journal for ImmunoTherapy of Cancer

FDA Approval Summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors

(2019) Leigh Marcus et al.   CLINICAL CANCER RESEARCH

Predicting Response to Cancer Immunotherapy using Non-invasive Radiomic Biomarkers

(2019) S Trebeschi et al.   ANNALS OF ONCOLOGY

Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Non–Small Cell Lung Cancer

(2019) Mohammadhadi Khorrami et al.   Cancer Immunology Research

The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors

(2019) Andrew A. Davis et al.   Journal for ImmunoTherapy of Cancer

Radiomics of 18F-FDG PET/CT images predicts clinical benefit of advanced NSCLC patients to checkpoint blockade immunotherapy

(2019) Wei Mu et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

(2018) Matthew D. Hellmann et al.   CANCER CELL

Biomarkers of response to immune checkpoint blockade in cancer treatment

(2018) Takeo Fujii et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study

(2018) Roger Sun et al.   LANCET ONCOLOGY

High response rate to PD-1 blockade in desmoplastic melanomas

(2018) Zeynep Eroglu et al.   NATURE

Radiomics of Brain MRI: Utility in Prediction of Metastatic Tumor Type

(2018) Helge C. Kniep et al.   RADIOLOGY

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

(2017) I. Puzanov et al.   Journal for ImmunoTherapy of Cancer

The Occurrence of Rare Cancers in U.S. Adults, 1995–2004

(2017) Robert T. Greenlee et al.   PUBLIC HEALTH REPORTS

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

(2016) Antoni Ribas et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

The promise and challenges of rare cancer research

(2016) Kimberly M Komatsubara et al.   LANCET ONCOLOGY

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial

(2016) Sarah B Goldberg et al.   LANCET ONCOLOGY

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

(2016) Paul T. Nghiem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative

(2015) Jan Bogaerts et al.   EUROPEAN JOURNAL OF CANCER

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

Radiomics: Extracting more information from medical images using advanced feature analysis

(2012) Philippe Lambin et al.   EUROPEAN JOURNAL OF CANCER

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

(2011) Omid Hamid et al.   Journal of Translational Medicine

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH